Home > Documents in Process > Paraneoplastic Lambert-Eaton myasthenic syndrome associated with non-small cell lung cancer: data from the European LEMS registry and systematic review. > print

001     282604
005     20251211161805.0
024 7 _ |a 10.1186/s42466-025-00453-5
|2 doi
024 7 _ |a pmid:41361909
|2 pmid
024 7 _ |a pmc:PMC12687528
|2 pmc
037 _ _ |a DZNE-2025-01362
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Preßler, Hannah
|0 P:(DE-2719)9003388
|b 0
|e First author
|u dzne
245 _ _ |a Paraneoplastic Lambert-Eaton myasthenic syndrome associated with non-small cell lung cancer: data from the European LEMS registry and systematic review.
260 _ _ |a [London]
|c 2025
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765466141_17919
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Paraneoplastic Lambert-Eaton myasthenic syndrome (pLEMS) is well-established in small-cell lung cancer (SCLC), but data on other malignancies are limited. We aimed to define the clinical phenotype of pLEMS in non-SCLC cancers (non-SCLC-pLEMS) relative to SCLC-associated LEMS (SCLC-pLEMS) and autoimmune LEMS (aiLEMS).Retrospective analysis was conducted to compare patients with SCLC-pLEMS, aiLEMS and non-SCLC-pLEMS from the European LEMS registry, and further non-SCLC-pLEMS cases were identified by a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.The registry included 72 aiLEMS, 12 SCLC-pLEMS, and 11 non-SCLC-pLEMS patients. LEMS preceded cancer diagnosis in 33% of SCLC-pLEMS (median 2 months) and 30% of non-SCLC-pLEMS (median 15 months), was concurrent in 25% and 30% and followed tumor diagnosis in the remainder. At study enrollement, Quantitative Myasthenia Gravis (QMG) scores were higher in SCLC-pLEMS (median 12, range 1-24) with recent tumor therapy initiation (median 3 months), and lower in non-SCLC-pLEMS (median 6, range 0-19), with longer (median 12 months) or completed tumor therapy, and aiLEMS (median 5, range 0-23). During follow-up, QMG improved with tumor therapy, and worsened with recurrence/progression in pLEMS groups. After completion of cancer treatment, QMG values in SCLC-pLEMS (median 6, range 0-19) and non-SCLC-pLEMS (median 5, range 1-22) were comparable to each other and to aiLEMS (median 7, range 0-29). Ataxia was significantly more frequent in SCLC-pLEMS (64%) and non-SCLC-pLEMS (55%) than in aiLEMS (19%, p = 0.006 and p = 0.024). Another 115 literature-reported non-SCLC-pLEMS cases were identified (total n = 126, comprising 137 tumors). Most common were non-small cell lung cancer (NSCLC) (n = 25, 18%), Merkel cell carcinoma (n = 18, 13%) and lymphoproliferative disorders (n = 15, 11%). In 52 literature-reported LEMS patients with outcome data, 88% partially or fully recovered after tumor therapy, leaving the paraneoplastic origin uncertain in many.Our results suggest that, beyond SCLC, other tumors can trigger pLEMS. Compared with aiLEMS, non-SCLC-pLEMS and SCLC-pLEMS showed a higher frequency of ataxia, and LEMS severity tended to reflect tumor treatment status, while disease severity becomes comparable across subtypes after cancer therapy. The frequent improvement of symptoms with tumor-directed treatment supports extended screening beyond SCLC and timely management.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Ataxia
|2 Other
650 _ 7 |a Cancer treatment
|2 Other
650 _ 7 |a Lambert-Eaton myasthenic syndrome
|2 Other
650 _ 7 |a Paraneoplastic
|2 Other
650 _ 7 |a Tumor
|2 Other
700 1 _ |a Haddy, Imène
|b 1
700 1 _ |a Daugherty, Claire
|b 2
700 1 _ |a Postila, Ville
|b 3
700 1 _ |a Meisel, Andreas
|b 4
773 _ _ |a 10.1186/s42466-025-00453-5
|g Vol. 7, no. 1, p. 95
|0 PERI:(DE-600)2947493-0
|n 1
|p 95
|t Neurological research and practice
|v 7
|y 2025
|x 2524-3489
856 4 _ |u https://pub.dzne.de/record/282604/files/DZNE-2025-01362.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/282604/files/DZNE-2025-01362.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9003388
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:42:53Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:42:53Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-04-10T15:42:53Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-04-10T15:42:53Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2024-12-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-30
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-30
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-30
920 1 _ |0 I:(DE-2719)1810003
|k AG Prüß
|l Autoimmune Encephalopathies
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1810003
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21